Bendamustine Treatment before CAR T-Cell Therapy May Be Detrimental
Vall d'Hebron Institute of Oncology
CAR T-cell therapy recipients with refractory lymphoma showed poorer treatment outcomes when treated with bendamustine
Lymphoma
New First-Line Lymphoma Treatment Well-Tolerated in Phase 2 Trial
PrECOG Cancer Research Group
Venetoclax administered with bendamustine+rituximab as the first therapy for mantle cell lymphoma led to 85 percent complete response rate
Novel Protein Inhibitor Shows Antitumor Activity in Patients with NHL
Vall d'Hebron Institute of Oncology
Monotherapy with new PRMT5 inhibitor well tolerated with low toxicity in adults with B cell non-Hodgkin lymphomas
Initiating r/r Lymphoma Treatment in Women: During vs. After Gestation
American Society of Hematology
Fighting relapsed/refractory lymphoma during pregnancy requires critical decision-making from patients and providers
Car-T Therapy Improves Outcomes for Patients with B-Cell Lymphoma
University of Chicago Medical Center
Forty percent of patients with diffuse large B-cell lymphoma had a complete response, most of which were durable